Merck & Co., Inc: HIV Infections trials

The registry lists 75 HIV Infections studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 29 have results posted.

Phase 1 11Phase 2 25Phase 3 21Phase 4 4No phase 14(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kgNot yet recruitingNCT07862569Phase 2
• Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedNCT04223791Phase 3Results posted
• Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)CompletedNCT04223778Phase 3Results posted
• Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)TerminatedNCT03960541Phase 2Results posted
• The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)CompletedNCT02473367Phase 1Results posted
• Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)CompletedNCT02131233Phase 3Results posted
• Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedNCT02116660Phase 2Results posted
• A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)CompletedNCT01930045Phase 1Results posted
• Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)TerminatedNCT01814722Results posted
• A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)CompletedNCT01717287Phase 2Results posted
• A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)CompletedNCT01632345Phase 2Results posted
• A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)CompletedNCT01622673Phase 1Results posted
• Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)CompletedNCT01048671Results posted
• A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)CompletedNCT01000818Phase 1Results posted
• A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)CompletedNCT00959699Phase 2Results posted
• A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)CompletedNCT00849680Phase 1Results posted
• A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)TerminatedNCT00745823Phase 3Results posted
• Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584)CompletedNCT00736242Results posted
• Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)TerminatedNCT00687544Phase 4Results posted
• Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100)CompletedNCT00686829Phase 2Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)TerminatedNCT00443729Phase 3Results posted
• MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)TerminatedNCT00443703Phase 3Results posted
• A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)CompletedNCT00369941Phase 3Results posted
• Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)TerminatedNCT00350623Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)CompletedNCT00293267Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)CompletedNCT00293254Phase 3Results posted
• Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)CompletedNCT00243230Phase 2Results posted
• Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)CompletedNCT00105157Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)CompletedNCT00100048Phase 2Results posted
• Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)TerminatedNCT00095576Phase 2Results posted
• MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)CompletedNCT07042945Phase 1
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)Active, not recruitingNCT05766501Phase 3
• Stocrin Re-examination Study (0831-028)CompletedNCT01065792
• Isentress Re-examination Study (MK-0518-115)CompletedNCT01042808
• Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)CompletedNCT00850616Phase 1
• A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)CompletedNCT00849732Phase 1
• Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)CompletedNCT00705419
• Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)CompletedNCT00632073Phase 1
• Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)CompletedNCT00551330Phase 2
• Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)CompletedNCT00551018Phase 2
• Pediatric Expanded Access Program-Oral Solution (0831-908)CompletedNCT00543530Phase 3
• A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)CompletedNCT00541463Phase 2
• Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)CompletedNCT00523211Phase 3
• Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)CompletedNCT00474370Phase 3
• Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)WithdrawnNCT00381017Phase 3
• Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)Approved for marketingNCT00377065
• Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285WithdrawnNCT00243568Phase 3
• Phase III PEG-Intron in HIV-infected Patients (Study P00738)CompletedNCT00035360Phase 3
• A Study of the Side Effects of L-743,872 in Men With Candidal EsophagitisCompletedNCT00005921Not applicable
• Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With FluconazoleTerminatedNCT00005920Phase 2
• The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention TreatmentStatus unknownNCT00005118Phase 2
• Safety and Effectiveness of PEG-Intron in HIV-Infected PatientsCompletedNCT00005012Phase 2
• A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken IndinavirCompletedNCT00002452Phase 2
• Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV DrugsStatus unknownNCT00002451Phase 2
• Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive PatientsCompletedNCT00002446Phase 3
• The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsCompletedNCT00002443Not applicable
• A Study to Compare the Effectiveness of Two Anti-HIV Drug CombinationsCompletedNCT00002430Not applicable
• A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and LamivudineSuspendedNCT00002424Phase 2
• A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected PatientsCompletedNCT00002406Phase 3
• A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive PatientsCompletedNCT00002399Phase 2
• The Safety and Effectiveness of Indinavir Sulfate Plus EfavirenzCompletedNCT00002387Not applicable
• Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With HemophiliaCompletedNCT00002386Phase 4
• The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected PatientsCompletedNCT00002376Phase 4
• Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected PatientsCompletedNCT00002375Not applicable
• Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease InhibitorsCompletedNCT00002361Phase 2
• A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive PatientsCompletedNCT00002354Not applicable
• A Study of L-735,524 in HIV-Positive Children and AdolescentsCompletedNCT00002351Phase 1
• Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice DailyStatus unknownNCT00002241Phase 2
• A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease InhibitorsCompletedNCT00002235Phase 2
• Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With NelfinavirCompletedNCT00002220Phase 3
• A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TCCompletedNCT00002208Phase 3
• The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of InfectionCompletedNCT00002179Phase 4
• A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TCCompletedNCT00002155Not applicable
• Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV RetinitisCompletedNCT00002070Phase 3
• A Pharmacokinetic Study of L-697,661 Alone and in Combination With ZidovudineCompletedNCT00000628Phase 1